Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension

The Post Marketing Surveillance Study Conducted With a Continuous Enrollment Method to Assess Serious Adverse Events, Adverse Events, Safety, Efficacy of Micardis Tablet (Telmisartan 20, 40, 80mg p.o. Once Daily Over 2 Weeks)

The objective of this PMS study was to monitor and assess the safety of Micardis tablets in patients with hypertension over a period of 6 years

Inclusion Criteria:

• Male and female patients diagnosed with essential hypertension
• Patients without prior experience with Micardis tablet

Exclusion Criteria:

• Known hypersensitivity to Micardis tablet
• Pregnancy or breastfeeding
• Biliary atresia
• Severe hepatic failure patients
• Severe renal failure patients